X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.17) by 17.65 percent. This is a 100 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $1.43 million which beat the analyst consensus estimate of $1.04 million by 37.75 percent.